OptiNose (NASDAQ:OPTN) will release its earnings data before the market opens on Wednesday, May 5th. Analysts expect OptiNose to post earnings of ($0.51) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.
OptiNose (NASDAQ:OPTN) last posted its quarterly earnings data on Tuesday, March 2nd. The company reported ($0.46) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.46). The firm had revenue of $16.35 million during the quarter, compared to the consensus estimate of $18.25 million. OptiNose had a negative return on equity of 294.64% and a negative net margin of 230.14%. On average, analysts expect OptiNose to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
OPTN opened at $3.44 on Tuesday. The business has a 50 day moving average price of $3.62 and a two-hundred day moving average price of $4.02. The company has a quick ratio of 3.76, a current ratio of 3.98 and a debt-to-equity ratio of 3.79. The company has a market cap of $182.71 million, a PE ratio of -1.56 and a beta of 1.03. OptiNose has a 52 week low of $3.14 and a 52 week high of $10.00.
In related news, CEO Peter K. Miller sold 9,695 shares of the company’s stock in a transaction that occurred on Monday, March 15th. The stock was sold at an average price of $3.92, for a total value of $38,004.40. Following the sale, the chief executive officer now owns 624,426 shares in the company, valued at approximately $2,447,749.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 20,690 shares of company stock valued at $81,105. Company insiders own 38.00% of the company’s stock.
OptiNose Company Profile
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.